Oroxin B
Based on 6 publication(s) in Google Scholar
Oroxin B (OB) is a BBB-permeable flavonoid isolated from traditional Chinese herbal medicine Oroxylum indicum (L.) Vent. Oroxin B (OB) possesses obvious inhibitory effect and induces early apoptosis rather than late apoptosis on liver cancer cells through upregulation of PTEN, down regulation of COX-2, VEGF, PI3K, and p-AKT. Oroxin B (OB) selectively induces tumor-suppressive ER stress in malignant lymphoma cells.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.39%
- CAS No.: 114482-86-9
- Formule: C27H30O15
- Masse moléculaire:594.52
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Differentiation Inducing Compound Library
HY-L038
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Endoplasmic Reticulum Stress Compound Library
HY-L054
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Pyroptosis Compound Library
HY-L059
-
Cytoskeleton Compound Library
HY-L060
-
Orally Active Compound Library
HY-L061
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Cancer Natural Product Library
HY-L107
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Membrane Protein-targeted Compound Library
HY-L149
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Anti-Brain Cancer Compound Library
HY-L188
-
Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library
HY-L194
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Posttranslational Modification Library
HY-L226
-
Mongolian Medicine Compound Library
HY-L238
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Stem Cell Signaling Compound Library
HY-L017
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Autophagy Compound Library
HY-L029
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) Oroxin B
More
Customer Validation & Images
-
Cell Migration/Invasion Assay
-
Cell Imaging/Staining
-
WB
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Activité biologique
Oroxin B (0-2 μM, 48 h) inhibits the proliferation (48 h), and induces apoptosis (12 h) of the human hepatoma cell line (SMMC 7721)[1].
Oroxin B (0-2 μM, 48 h) increases PTEN and inhibits COX-2, VEGF, p-AKT, and PI3K in SMMC 7721[1].
Oroxin B (0-30 μM, 48 h) selectively induces ER stressin (stress marker: glyburide labeled by rhodamine) in Raji cell[2].
Oroxin B (160 μM, 24 h) inhibits IL-1β induced inflammation-related (iNOS, COX-2, TNF-α, IL-6, and IL-1β) markers in chondrocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Raji cells
-
Concentration:0-40 μM
-
Incubation Time:48 h
-
Result:Decreased ER stress master genes (GRP78 and ATF6) mRNA level.
Oroxin B (160 μM of 10 μL, injected into the knee joints of mice) protects articular cartilage in destabilized medial meniscus (DMM) induced mice OA[3].
Oroxin B (200 mg/kg/day, oral gavage) relieves hepatic inflammation and inhibits MAFLD progression in HFD-fed rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human lymphoma cell (Raji cell) xenograft model[2]
-
Dosage:30 mg/kg
-
Administration:i.p., 28 days
-
Result:Induced malignant lymphoma cell ER stress.
Inhibited tumor growth.
Prolonged overall survival of tumor-bearing mice.
-
Animal Model:HFD-fed rats[4]
-
Dosage:200 mg/kg/day
-
Administration:oral gavage
-
Result:Reduced the levels of plasma lipids, LPS, IL-6, and TNF-α.
Inhibited liver fibrosis by reducing collagen deposition.
Chemical Information
-
CAS No. 114482-86-9
-
Appearance Solid
-
Masse moléculaire 594.52
-
Formule C27H30O15
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=CC=C2)OC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]5[C@@H]([C@H]([C@@H]([C@@H](CO)O5)O)O)O)O4)O)O)O)=C(O)C(O)=C13
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Autophagy
Chaperone-mediated autophagy reprograms heterogeneous subsets of activated macrophages in immune thrombocytopenia. [Abstract]2026 Jun 26:1-17. PMID: 42329073 -
Asian J Pharm Sci
Enhancing HepG2 cell apoptosis with a combined nanoparticle delivery of miR-128-3p agomir and Oroxin B: A novel drug delivery approach based on PI3K-AKT and VEGF pathway crosstalk. [Abstract]2025 Jun;20(3):100909. PMID: 40487120
Oroxin B purchased from MedChemExpress. Usage Cited in: Asian J Pharm Sci. 2025 Jun;20(3):100909. [Abstract]
Effects of NA-miR-128–3p and Oroxin B (OXB) (20 μM) on HepG2 cells examined by scratch wound healing assay.
Oroxin B purchased from MedChemExpress. Usage Cited in: Asian J Pharm Sci. 2025 Jun;20(3):100909. [Abstract]
Clone forming assay was carried out to evaluate proliferation of HepG2 cells. Cells (1000/well) were inoculated into complete medium within the 12-well plate until adherence treated with Oroxin B (OXB) (20 μM).
Oroxin B purchased from MedChemExpress. Usage Cited in: Asian J Pharm Sci. 2025 Jun;20(3):100909. [Abstract]
Co-treatment with NA-miR-128–3p and Oroxin B (OXB) (40 nM) attenuated the expression of AKT1 and VEGF1 in HepG2 cells.
Oroxin B purchased from MedChemExpress. Usage Cited in: Asian J Pharm Sci. 2025 Jun;20(3):100909. [Abstract]
Relative tumor volume treated with Oroxin B (OXB) (19.8 mM/kg, tail vein).
Oroxin B purchased from MedChemExpress. Usage Cited in: Asian J Pharm Sci. 2025 Jun;20(3):100909. [Abstract]
H&E staining in mouse tumor tissue treated with Oroxin B (OXB) (19.8 mM/kg, tail vein).
-
Food Chem
Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]2025 Dec 30:497:146992. PMID: 41285060 -
Food Chem
Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]2025 Oct 15:489:144992. PMID: 40466530 -
Mol Med Rep
Regulation of the PTEN/PI3K/AKT pathway in RCC using the active compounds of natural products in vitro. [Abstract]2021 Nov;24(5):766. PMID: 34490473 -
Solvant et solubilité
DMSO : 100 mg/mL (168.20 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (283 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Li NN, et al. Evidence for the Involvement of COX-2/VEGF and PTEN/Pl3K/AKT Pathway the Mechanism of Oroxin B Treated Liver Cancer. Pharmacogn Mag. 2018 Apr-Jun;14(54):207-213. [Content Brief]
[2]. Yang P, et al. Oroxin B selectively induces tumor-suppressive ER stress and concurrently inhibits tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy. Toxicol Appl Pharmacol. 2015 Oct 15;288(2):269-79. [Content Brief]
[3]. Lu R, et al. Oroxin B alleviates osteoarthritis through anti-inflammation and inhibition of PI3K/AKT/mTOR signaling pathway and enhancement of autophagy. Front Endocrinol (Lausanne). 2022 Dec 1;13:1060721. [Content Brief]
[4]. Huang Y, et al. Oroxin B improves metabolic-associated fatty liver disease by alleviating gut microbiota dysbiosis in a high-fat diet-induced rat model. Eur J Pharmacol. 2023 Jul 15;951:175788. [Content Brief]
[5]. Niu K, et al. Pharmacokinetics and tissue distribution of oroxin B in rats using a validated LC-MS/MS assay. Biomed Chromatogr. 2019 Mar;33(3):e4417. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6820 mL | 8.4101 mL | 16.8203 mL | 42.0507 mL |
| 5 mM | 0.3364 mL | 1.6820 mL | 3.3641 mL | 8.4101 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6820 mL | 4.2051 mL | |
| 15 mM | 0.1121 mL | 0.5607 mL | 1.1214 mL | 2.8034 mL | |
| 20 mM | 0.0841 mL | 0.4205 mL | 0.8410 mL | 2.1025 mL | |
| 25 mM | 0.0673 mL | 0.3364 mL | 0.6728 mL | 1.6820 mL | |
| 30 mM | 0.0561 mL | 0.2803 mL | 0.5607 mL | 1.4017 mL | |
| 40 mM | 0.0421 mL | 0.2103 mL | 0.4205 mL | 1.0513 mL | |
| 50 mM | 0.0336 mL | 0.1682 mL | 0.3364 mL | 0.8410 mL | |
| 60 mM | 0.0280 mL | 0.1402 mL | 0.2803 mL | 0.7008 mL | |
| 80 mM | 0.0210 mL | 0.1051 mL | 0.2103 mL | 0.5256 mL | |
| 100 mM | 0.0168 mL | 0.0841 mL | 0.1682 mL | 0.4205 mL |
Oroxin B Related Classifications
HY-N1435 Related Classifications
Powered by Bioz